v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities:        
Net loss $ (8,704) $ (10,781) $ (39,224) $ (17,802)
Adjustments to reconcile net loss to net cash used in operating activities:        
Compensation expense recognized for the issuance of shares and warrants in connection with the sale of a previously controlled subsidiary     7,000
Gain on debt extinguishment, net     (278)
Loss on debt extinguishment, net     707
Realized gain on short-term investments     (8)
Loss on equity method investment 154 403
Gain on waiver of accrued interest (371) (371)
Unrealized foreign exchange (gain) loss (27) (16) 13
Loss (gain) on change in fair value of convertible notes payable     2,737 (2,018)
Gain on change in fair value of derivative warrant liability (137) (138) (221)
Loss on issuance of warrants     2,710
Non-cash lease expense 70 60 125 89
Stock-based compensation expense 398 394 2,183 1,632
Issuance of common stock for licensing right     1,568
Non-cash interest expense 126 224 253 536
Depreciation expense 12 10 21 10
Amortization of financed directors and officers insurance 621 739 1,440 1,666
Amortization expense     2,404 447
Issuance of common stock for services 530 1,152
Issuance of common stock for services - related party     2,097
Amortization expense 1,008 1,015 929
Gain (loss) on issuance of common stock for services     (70) 202
Changes in operating assets and liabilities:        
Prepaid expenses and other current assets (669) 198 (4,062) (2,273)
Accounts payable 1,833 (236) 434 1,225
Accrued expenses and other liabilities 446 (136) (1,114) 1,030
Accrued litigation liability     9,594
Lease liability (69) (58) (125) (124)
Net cash flows used in operating activities (2,438) (6,509) (15,555) (9,682)
Cash flows from investing activities:        
Purchase of digital assets     (1,998)
Proceeds from disposal of digital assets     1,595
Purchases of equipment and clinical assets (405) (405) (51)
Purchases of short-term investments     (490)
Proceeds from the sale of short-term investments     498
Net cash flows used in investing activities (405) (808) (43)
Cash flows from financing activities:        
Net proceeds from the issuance of notes payable 1,801 3,226
Proceeds from issuance of common shares related to the ATM program 355 11,948 19,699 3,328
Exercise of warrants     176
Repayment of notes payable (156) (158) (776)
Proceeds from issuance of warrants     113
Repayment of notes payable – related parties (482) (425) (425)
Repayment of convertible notes payable – related parties (927) (927)
Repayment of convertible notes payable (650) (661)
Purchases of treasury stock     (106)
Net cash flows provided by financing activities 1,674 9,684 17,422 6,067
Net change in cash and cash equivalents before effect of exchange rate changes (764) 2,770 1,059 (3,658)
Effect of exchange rate changes on cash and cash equivalents 2 8 (104) (16)
Net change in cash (762) 2,778 955 (3,674)
Cash and cash equivalents at beginning of period 1,509 554 554 4,228
Cash and cash equivalents at end of period 747 3,332 1,509 554
Right of Use Asset obtained in exchange for Operating Lease Liabilities     352
Correction of immaterial error related to franchise tax expense     144
Issuance of Common Stock upon exercise of conversion option 2,418 5,953 7,145 92
Issuance of Common Stock in exchange for debt extension     489
Shares cancelled     (106)
Conversion of deferred commission payable to convertible promissory note     5,378
Supplemental cash flow information:        
Cash paid for interest 11 80
Loss (gain) on debt extinguishment, net 1,073 (278)    
Change in fair value of convertible notes payable 733 2,875    
Purchases of treasury stock   (106)    
Cash paid for taxes
Non-cash investing and financing activities        
Issuance of common stock upon exercise of conversion option 2,418 5,950    
Issuance of common stock for services 530 2,951    
Issuance of common stock for investment in related party 622    
Deferred cash payable for investment in related party 8,000    
Issuance of pre-funded warrants for investment in related party 114,378    
Issuance of warrants upon the issuance of convertible note $ 264